PAXLOVID

Mel reviews the newest antiviral for COVID "Ritonavir" PAXLOVID. 

Reference: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate

John C., P.A. -

This was an interim analysis of 1219 patients but if you add the treatment arm and the placebo arm denominators, you only get 783. Do we know what happened to the other 436?

Mel H. -

This part of the numbers adds up - but it is very confusing as they present only partial data.

"The statistical significance of these results was high (p<0.0001). Similar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset; 1.0% of patients who received PAXLOVID™ were hospitalized through Day 28 following randomization (6/607 hospitalized, with no deaths), compared to 6.7% of patients who received a placebo (41/612 hospitalized with 10 subsequent deaths), with high statistical significance (p<0.0001). In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID™ as compared to 10 (1.6%) deaths in patients who received placebo."

To join the conversation, you need to subscribe.

Sign up today for full access to all episodes and to join the conversation.

To download files, you need to subscribe.

Sign up today for full access to all episodes.
Mobile Video (180p) 4.12 MB - MP4Small Video (400p) 8.48 MB - MP4Standard Video (720p) 14.6 MB - MP4HD Video (1080p) 34.6 MB - MP4